Papers/PMID:33067289
Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.
BMJ open2020The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
N-acetyl-L-cysteine — decreases acute kidney injury incidence (any grade)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01) and all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01).”
Quoted verbatim from Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.. - Study
- meta-analysis
- Population
- Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, seven randomised trials pooled
Effect 0.51 risk ratio, 95% CI 0.31 to 0.82
Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.2020PMID:33067289Permalink
N-acetyl-L-cysteine — decreases all-cause mortality
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01) and all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01).”
Quoted verbatim from Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.. - Study
- meta-analysis
- Population
- Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, seven randomised trials pooled; in-hospital mortality horizon
Effect 0.37 risk ratio, 95% CI 0.17 to 0.79
Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.2020PMID:33067289Permalink